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Introduction
The increasing prevalence and morbidity have made diabetes 
one of the biggest health care challenges of the 21st century.1 
Both environmental (sedentary lifestyle, excessive calorie 
intake) and genetic factors contribute to this global epidemic.2 
Therefore, lifestyle and pharmacological interventions are 
needed for management of diabetes and delaying progression of 
its related metabolic comorbidities. The undesirable side effects 
associated with oral glucose lowering medications3 and the pro-
gressive nature of Type 2 diabetes4 exacerbate the need for new 
treatment options with improved therapeutic profile. Although 
incretin mimetic drugs offer a broad range of benefits by target-
ing multiple tissues,5 their gastrointestinal side effects can limit 
clinical efficacy. In addition, the magnitude of antidiabetic effi-
cacy demonstrated in preclinical trials has not fully translated to 
the clinical setting.6 Roux-en-Y gastric bypass (RYGB) surgery 
is now being regarded as the gold standard technique for obesity 
and diabetes treatment, resulting in approximately 88% diabetes 
remission, subsequent weight loss, and superior metabolic con-
trol than conventional pharmacological treatments.7-9 Ongoing 
research highlights the key role of gut hormones in improving 
metabolic dysfunction post bariatric surgeries.10,11 Therefore, it 
is suggested that synergistic manipulation of multiple gut hor-
mone signalling pathways may offer similar therapeutic efficacy 
as surgical procedures, in turn providing obvious respite across 
several aspects of the metabolic syndrome.
Gut Hormones Interplay Post Bariatric Surgeries
Type 2 diabetes remission following bariatric surgery is inde-
pendent of weight loss and includes mechanisms such as 
enhanced glycemic control,8 improved insulin sensitivity,12 aug-
mented pancreatic beta-cell function,13 restored first-phase insu-
lin secretion,14 and decreased truncal fat deposition.15 Altered 
secretion and action of gut-derived hormones such as peptide 
YY (PYY), glucagon-like peptide-1 (GLP-1), glucose-depend-
ent insulinotropic peptide (GIP), oxyntomodulin (OXM), chol-
ecystokinin (CCK), and ghrelin after metabolic surgery is now 
being linked to Type 2 diabetes remission.11,16,17 This suggests 
that superior metabolic improvement post bariatric surgery is a 
result of interplay between gut hormones and subsequent re-
programming of neuroendocrine signals. Despite these advan-
tages, bariatric surgeries are invasive to patients, costly, and may 
result in complications such as kidney stones, abdominal pain, 
reduction of bone density, and vitamin deficiencies.18 Thus, 
non-invasive and novel antidiabetic therapies that target similar 
peptide hormone pathways, either through individual peptide 
analogue administration or more interestingly via a hybrid pep-
tide approach, have distinct therapeutic utility for Type 2 diabe-
tes. Indeed, coadministration of different gut hormones, such as 
GLP-1, GIP, PYY, and CCK alone and in combination with 
insulin, has previously been reported to maintain normoglyce-
mia and metabolic homeostasis in diabetes.19-22 The clinical suc-
cess of combined insulin and GLP-1 therapy (IDegLira) as a 
single-drug formulation in Type 1 diabetes patients further point 
to the importance of activating multiple signal transduction 
pathways for improved treatment outcomes.23
Unimolecular Poly-Agonist Approach
To combat reduced physiological concentrations of GLP-1 in 
Type 2 diabetes,24 various GLP-1 mimetics are currently 
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clinically available.25 However, these mimetics target a single 
specific pathway and as such fail to achieve the superior glucose 
homeostasis, enhanced satiety and increased weight loss associ-
ated with bariatric surgeries, that are known to target numer-
ous gut peptide–related cellular pathways.26,27 Therefore, 
strategies that can augment the antidiabetic actions of GLP-1 
drugs are of key interest. In line with this, coadministration of 
various gut hormones with GLP-119-23 have shown therapeutic 
promise; however, their clinical application is often restricted 
due to dissimilar pharmacokinetic properties of the constitu-
ents and unwanted peptide–peptide interactions.28 Recent 
years have seen remarkable progress in the development of 
multitargeting peptides by combining the key bioactive 
domains of gastrointestinal hormones into a single molecule. 
These multifunctional molecules exhibit a single pharmacoki-
netic profile together with synergistic pharmacological action 
(Figure 1). Owing to its well-established mechanistic path-
ways, most of these multiagonists have centered their structures 
around GLP-1.29-31 In addition, knowledge of truncated bioac-
tive forms32-34 of gut-derived peptides has also facilitated the 
cost-effective generation of hybrid peptides.
Dual-agonist peptides
GLP-1/glucagon. GLP-1/glucagon hybrid peptides have been 
generated to incorporate the glycemic and appetite suppressive 
effects of GLP-135,36 with lipolytic and thermogenic properties 
of glucagon.37,38 In keeping with this, various GLP-1/glucagon 
coagonists have been reported to normalize body weights, 
improve glucose tolerance, lipid profile and liver steatosis in 
rodents and non-human primates.39-42 Furthermore, when 
given in combination with PEGylated-leptin, a GLP-1/gluca-
gon hybrid synergistically lowered body weight by restoring 
leptin sensitivity in diet-induced obese (DIO) mice.43 Given 
their translational potential, several GLP-1/glucagon agonists 
with optimized pharmacokinetic profile are currently being 
evaluated in clinical trials.44 A recent success story is 
MEDI0382, a balanced GLP-1 and glucagon receptor dual-
agonist that improved glycemic control and induced signifi-
cantly higher reductions of bodyweight in obese patients with 
Type 2 diabetes when compared to placebo group (−3.8 kg 
mean for MEDI0382 vs −1.7 kg mean for placebo).45 More 
recently, SAR425899, another GLP-1/glucagon agonist, was 
reported to significantly reduce fasting glucose and HbA1c 
levels in patients with Type 2 diabetes. SAR425899 not only 
was well-tolerated but also promoted body weight reductions 
in healthy volunteers and in patients with Type 2 diabetes.46 In 
addition, GLP-1/glucagon agonism has also shown therapeu-
tic potential in non-alcoholic steatohepatitis and liver regen-
eration in preclinical research.47 This indicates that by targeting 
multiorgan receptors, these peptides offer a more comprehen-
sive beneficial profile in metabolic dysregulation.
GLP-1/GIP. Both GIP and GLP-1 are incretin hormones 
released postprandially to regulate blood glucose levels.48 Type 
2 diabetes patients have an inherent incretin defect arising 
from decreased GLP-1 secretion and reduced insulinotropic 
action of GIP.49 It is primarily this reason that GIP analogues 
have been discounted as Type 2 diabetes therapy.48 In addition, 
the discrepancies seen in preclinical genetic knockout models 
and in the use of GIP receptor agonism or antagonism for 
metabolic regulation50 have further undermined the clinical 
Figure 1. This scheme demonstrates how peptide/peptide multiagonist approaches offer beneficial metabolic profile by targeting multiple receptor 
pathways and can be harnessed as obesity and diabetes therapeutics. CCK indicates cholecystokinin; GIP, glucose-dependent insulinotropic polypeptide; 
GLP-1, glucagon-like-peptide-1.
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utility of GIP analogues. In this regard, polypharmacy may 
help in unveiling the therapeutic potential of this rather 
ambiguous GIP system, as was seen previously with beneficial 
synergistic effects of GIP and GLP-1 coadministration.20 
Glucagon-like-peptide-1/glucose-dependent insulinotropic 
polypeptide hybrid peptides activate both arms of the incretin 
axis (hence termed as Twincretins)28 and synergistically target 
the main hallmarks of metabolic syndrome including obesity, 
hyperglycemia, and dyslipidemia.28,51,52 Of mention is RG7697 
(also known as NNC0090-2746), which was well-tolerated in 
Type 2 diabetes patients and displayed improved glycemic con-
trol and greater body weight reductions than placebo group.51,53 
Another long-acting GIPR/GLP-1R agonist—LY3298176 
(another name tirzepatide)—offers once-weekly administra-
tion and has been reported to concentration-dependently 
reduce HbA1c levels, body weight, fasting, and postprandial 
plasma glucose in Type 2 diabetes patients54,55 and has now 
progressed to long-term clinical safety trials. Interestingly, 
LY3298176 displayed a broader therapeutic window than that 
of a selective GLP-1 receptor agonist, as only the highest dose 
of LY3298176 (15 mg) showed greater gastrointestinal adverse 
events than dulaglutide (1.5 mg), and doses of 10 mg and less 
were not significantly different.55 In addition to regulating 
body weight and glucose metabolism, GLP-1/GIP coagonism 
with a single hybrid peptide improved memory function in 
DIO mice56 and displayed neuroprotective effects in animal 
models of brain injury, Parkinson and Alzheimer disease,57-59 
further accentuating the superior metabolic profile associated 
with dual-receptor activation. Taken together, the strategy of 
harnessing synergistic antidiabetic effects of both arms of the 
incretin axis would help to sustain metabolic control by mim-
icking the native physiological incretin response.
GLP-1/CCK. CCK is an anorexigenic hormone secreted from 
enteroendocrine I-cells.60 CCK-8 is the major circulating form 
in plasma and inhibits food intake by binding to CCK-A 
receptors.60 In addition, benefits of GLP-1 at the level of the 
beta-cell have been suggested to be linked to a GLP-1/CCK 
intraislet loop.61 The combined treatment of CCK with GLP-1 
analogues in rodent models significantly lowered circulating 
glucose levels, improved glucose tolerance, and induced greater 
weight loss and appetite suppressive effects when compared 
with individual treatments.62,63 In keeping with such evidence 
of synergistic metabolic actions, the potential of a novel hybrid 
peptide that incorporates the key bioactive regions of (pGlu-
Gln)-CCK-8 and exendin-4 was investigated.31 By simultane-
ous activation of both GLP-1 and CCK-A receptors, this 
coagonist outperformed exendin-4 in terms of satiety and body 
weight reductions in DIO mice.31 Other beneficial effects of 
(pGluGln)-CCK-8/exendin-4 included prominent glucose 
homeostasis and reduced HbA1c and triglyceride levels, as well 
as improvements of insulin action and glucose disposal.31 In a 
recent study by Hornigold et  al,64 another hybrid peptide, 
named C2816 generated by combining stabilized GLP-1R 
agonist (AC3174) and a CCK-AR-selective agonist 
(AC170222), exhibited superior weight reductions when com-
pared with combined administration of the parent peptides in 
DIO mice. Although these initial observations clearly high-
light the synergistic metabolic benefits of unimolecular 
approach, further preclinical studies are necessary for compre-
hensive functional characterization of these GLP-1/CCK 
coagonists, particularly the combined effects of GLP-1 and 
CCK on the gallbladder would need to be carefully 
evaluated.65
GLP-1/gastrin. Gastrin, a CCK homologous peptide, is 
secreted from gastric G-cells and binds to CCK-B receptors, 
with a potential role in beta-cell regeneration.66 Coadministra-
tion of gastrin and GLP-1 resulted in improved beta-cell mass 
and survival in non-obese diabetic mice,67 paving way for a 
GLP-1 and CCK-B receptor dual-agonist, ZP3022.68 ZP3022 
reduced body weight, improved glucose tolerance, and increased 
beta-cell mass in db/db mice and Zucker diabetic fatty (ZDF) 
rats.68,69 While further studies are necessary to harness its 
potential as an antidiabetic pharmacotherapy, initial observa-
tions are encouraging.
GLP-1/xenin or GIP/xenin. Xenin is a 25-amino acid peptide 
hormone secreted into the bloodstream from the intestinal 
K-cells in response to food intake.70 Given the reduced insu-
linotropic effect of GIP, xenin is of key therapeutic significance 
for potentially overcoming GIP resistance in Type 2 diabetes 
patients.71,72 Indeed, glycemic normalization has been 
shown to restore GIP insulin-secretory function in Type 2 dia-
betes.73,74 GLP-1/xenin and GIP/xenin hybrids were gener-
ated by incorporating the key amino acid sequences of 
exendin-4 or (DAla)2 GIP with xenin-8-Gln,75,76 where 
xenin-8-Gln represents a stabilized fragment peptide of xenin 
that recapitulates the major biological functions of the parent 
peptide.77 Subchronic treatment with both xenin-based hybrid 
peptides displayed robust insulin secretory activity, improved 
glucose homeostasis, insulin sensitivity, and glucose tolerance 
in DIO mice.75,76 Notably, both hybrids augmented the bio-
logical response to native GIP in line with xenin’s GIP poten-
tiating capabilities.75,76 Together with efficient glucose 
homeostasis, the superior efficacy of both hybrids was also evi-
dent from the improved lipid profile75 and preserved pancreatic 
islet architecture.76 It is suggested that xenin-mediated effects 
occur via activation of neuronal signalling69; therefore, further 
studies are still required to disentangle the contribution of 
individual components of gut-brain axis for these observed 
metabolic effects. Although both activation and inhibition of 
GIP is postulated as a possible treatment option for Type 2 
diabetes and obesity,50,78-81 it is suggested from these studies 
that novel treatment options aimed at overcoming GIP resist-
ance in Type 2 diabetes may have therapeutic potential.
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GLP-1/amylin. The GLP-1/amylin hybrid peptide was engi-
neered to combine the pronounced antidiabetic therapeutic 
capacity of GLP-1 mimetic-exendin-4,82 with the satiety and 
weight-lowering properties of stable amylin analogue, davalin-
tide,83 within a single compound. These coagonists exhibited 
similar glycemic control as exenatide-treated group; however, 
their effects on body weight lowering were superior to exena-
tide or davalintide monotherapies in ob/ob mice and DIO 
rats.84 In a separate study, a PEGylated version of this hybrid 
with extended in vivo half-life showed enhanced glucose low-
ering and weight loss in rodents.85
Multiagonist peptides
The preclinical and clinical success of coagonist peptides dis-
cussed above has led to the development of novel triple-acting 
hybrids to achieve sustained metabolic improvements. One 
such example is GLP-1/Glucagon/GIP tri-agonists, where the 
main rationale was to incorporate the glucose lowering, insu-
linotropic, weight lowering and appetite suppressive effects of 
incretins with beneficial effects of glucagon on energy expendi-
ture and lipid metabolism.37,38,48 The sequence similarities 
between the glucagon family of peptides and receptors86 led to 
development of triple agonist peptides, namely YAG/glucagon, 
[DAla2]GIP/Oxm, and [DAla2]GLP-1/glucagon hybrids.30,87,88 
Using receptor transfected cells, receptor antagonists, and incre-
tin receptor knockout mice, all 3 hybrids were reported to acti-
vate GLP-1, GIP, and glucagon-signalling pathways.30,87,88 
Subchronic treatment with all 3 hybrid peptides displayed glu-
cose lowering, improved glucose tolerance, and insulinotropic 
effects in DIO mice,30,87,88 but only [DAla2]GIP/Oxm and 
[DAla2]GLP-1/glucagon hybrids caused body weight reduc-
tion. [DAla2]GLP-1/glucagon also improved insulin sensitivity 
in DIO mice.87
Similarly, another novel GLP-1/GIP/Glucagon hybrid 
was engineered based on the antidiabetic benefits of a previ-
ously validated GLP-1R/GIPR coagonist28 together with 
the notable metabolic advantages evoked through incor-
poration of a glucagon component. This triple-acting pep-
tide retained balanced GLP-1, GIP, and glucagon receptor 
activity in rodent beta-cells, adipocytes, and hepatocytes, 
respectively, suggesting simultaneous multiorgan receptor 
agonism.29 Although clear reductions in body weight and 
hepatic steatosis were evident in DIO mice, this was not the 
case in lean mice, implicating that tri-agonist exerts benefits 
only when coupled with metabolic dysregulation.29 Treatment 
with GLP-1/GIP/Glucagon triagonist also reduced pancre-
atic alpha-cell invasion to the islet core, thereby preserving 
the islet cyto-architecture in ZDF rats and db/db mice.29 
Notably, every other day treatment of HM15211, a long-
acting tri-agonist peptide conjugated to the human aglyco-
sylate Fc fragment, reduced body weight and glycemia and 
was more effective than daily administration of liraglutide in 
increasing energy expenditure in rodent models.89 Meanwhile, 
HM15211 and another triagonist, MAR423, have now 
entered phase 1 clinical trials.
To overcome the inherent GIP resistance in Type 2 diabe-
tes condition, a triple agonist peptide was engineered by com-
bining a previously characterized exendin-4/gastrin dual- 
agonist68 with xenin-8-Gln. Twice daily administration of 
exendin-4/gastrin/xenin-8-Gln decreased circulating glu-
cose, increased plasma insulin, reduced body fat mass, and 
improved glucose tolerance, insulin sensitivity, lipid profile, 
and metabolic response to GIP in DIO mice.90 Moreover, a 
stable and long-acting fatty acid-derivatized form, namely 
exendin-4/gastrin/xenin-8-Gln-Lys27 PAL, was developed to 
extend its bioactive profile for up to 12 hours; however, the 
fatty acid acylation did not impart any additional therapeutic 
benefits as first hoped for.91
Taken together, the use of multitargeting hybrid peptides 
that incorporate a GLP-1 backbone structure, linked to the 
bioactive region(s) of various other regulatory hormones, have 
shown remarkable therapeutic efficacy and offer viable alterna-
tive to bariatric surgery. In addition, given the nexus of PYY in 
diabetes remission post bariatric surgeries92 and the success of 
PYY, GLP-1, and/or OXM coadministration,12,93 PYY/GLP-
1-based coagonists may also be evaluated as a potent non-sur-
gical therapy for diabetes and obesity.
Although these preclinical studies highlight the efficacy of 
multiagonist peptides, there is often insufficient evidence as to 
whether the purported efficacy is being fractionally contrib-
uted by more than one component. Therefore, a major require-
ment for preclinical studies is to scrutinize balanced activity at 
individual key receptors, necessary for quantifying selective 
agonism and averting any off-target adverse events. In addi-
tion, the animal studies cannot capture the heterogeneity of 
human disease and such safety is difficult to predict and must 
be established in large, diverse chronic human studies. Indeed, 
despite their pharmacological benefits, the reports of pancrea-
titis and thyroid cancer post incretin mimetic treatments have 
raised safety concerns for their clinical use.94,95 The US Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMA) have since independently reviewed several 
clinical safety databases, pancreatic toxicology studies, and car-
diovascular outcome trials, and both agencies continue to 
investigate the pancreatic safety associated with incretin-based 
drugs; however, in light of the current knowledge, these con-
cerns have now been allayed.96,97 Therefore, an appropriate bal-
ance between potency and long-term safety must be established 
in clinical trials, before these multiaction peptides can be seri-
ously considered as registered antidiabetic drugs.
Future Directions
Single-molecule drugs targeting 2 or more gut-derived peptide 
hormone receptors have shown tremendous therapeutic poten-
tial, but the macromolecular nature of these drugs raises the 
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concerns of immunogenicity.98 Therefore, more extensive pre-
clinical assessment of these unimolecular multiagonists is 
essential to establish their translational efficiency to clinical 
settings. While animal studies are indispensable for optimizing 
novel drug candidates and to ascertain their human transla-
tional potential, there have been several incidences where drugs 
with promising preclinical data have failed in clinical trials,99 
hence a cautious interpretation of preclinical studies is required 
to ensure bench-to-bedside translation. A major challenge for 
translation of hybrid peptides from animal models to humans 
is the associated risk of cross-reactivity with other receptors 
leading to off-target effects.98 In this regard, receptor affinity 
studies in different aetiologies of diabetes are required to deci-
pher the complete metabolic efficacy and safety profile of these 
multitargeting hybrid peptides. Although various chemical 
modifications are being used to increase receptor binding, 
specificity, solubility, and protracted action, further chemical 
optimizations are still needed to achieve a more desirable phar-
macokinetic and pharmacodynamic profile of these multiact-
ing peptides. Mechanistic and receptor balance studies are 
necessary to help fine tune the most potent synergistic effects 
in vivo. Despite these cautions, the concurrent activation of 
multiple receptors by single-molecular entities has shown 
superior or equivalent efficacy compared to single-peptide ago-
nists (Table 1); however, species-specific receptor affinity and 
chronic safety need to be carefully evaluated before considering 
this multiple-targeting peptide strategy a viable therapeutic 
option for Type 2 diabetes.
Conclusion
The importance of combined actions of various regulatory 
peptide hormones for control of metabolism is slowly begin-
ning to come to light, particularly given recent knowledge 
gained from certain types of bariatric surgeries. While unimo-
lecular peptide approach seems to offer superior therapeutic 
efficacy, possibly reduced adverse effects, low dosage regimen 
when compared to individual peptide analogue administration, 
is patient friendly and may overcome the difficulties associated 
with solubility and dosage formulation of a mixture of 2 or 
more peptides when administered by single injection. However, 
careful outpatient clinical studies are still required to determine 
the sustainability, safety, and translational potential of these 
multiagonist drugs as novel class of antidiabetic and antio-
besity medications. Nevertheless, regulation of energy balance 
is a complex process involving multiple central and systemic 
tissues, and these unimolecular peptides may offer a more 
patient-centric non-surgical breakthrough for the treatment of 
obesity-linked metabolic disorders.
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